JPM26: Eli Lilly’s obesity drugs target commercial and governmental access

Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...
AOL

GLP-1 medications compared: Benefits and differences

GLP-1 medications have rapidly become some of the most influential treatments for Type 2 diabetes and weight loss. As more people look into these prescriptions, there is growing curiosity about how ...
Nasdaq

Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections

INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...
Newsday

FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes

The U.S. Food and Drug Administration approved a new type 2 diabetes drug, Trulicity, on Thursday. Trulicity is part of a class of once-a-week injectable drugs that help manage blood sugar levels in ...